INSERM, U866, Dijon, France. Faculté de Médecine, Université de Bourgogne, Dijon, France.
INSERM, U866, Dijon, France. Faculté de Médecine, Université de Bourgogne, Dijon, France. Centre Georges François Leclerc, Dijon, France.
Cancer Res. 2015 Feb 1;75(3):475-9. doi: 10.1158/0008-5472.CAN-14-2748. Epub 2015 Jan 14.
CD4 T cells are key components of the immune system that shape the anticancer immune response in animal models and in humans. The biology of CD4 T cells is complex because naïve T cells can differentiate into various subpopulations with various functions. Recently, a new population called Th9 cells was described. These cells are characterized by their ability to produce IL9 and IL21. They were first described in the context of parasite infections and allergic processes. However, some reports described their presence in the tumor bed in mice and humans. Their high secretion of IL9 and IL21 in the tumor bed contributes to their anticancer functions. Indeed, these cytokines trigger the activation of dendritic cells, mast cells, natural killer cells, and CD8 T cells to mount an antitumor immune response, thus explaining the remarkable ability of Th9 cells to control tumor growth. This review summarizes the latest advances in the Th9 field in cancer and focuses on their potential role as new tool for cell therapy.
CD4 T 细胞是免疫系统的关键组成部分，可在动物模型和人类中塑造抗肿瘤免疫反应。CD4 T 细胞的生物学特性非常复杂，因为初始 T 细胞可以分化为具有不同功能的各种亚群。最近，描述了一种称为 Th9 细胞的新群体。这些细胞的特征是能够产生 IL9 和 IL21。它们最初是在寄生虫感染和过敏过程的背景下描述的。然而，一些报告描述了它们在小鼠和人类肿瘤床中的存在。它们在肿瘤床中高分泌的 IL9 和 IL21 有助于发挥抗肿瘤功能。事实上，这些细胞因子触发树突状细胞、肥大细胞、自然杀伤细胞和 CD8 T 细胞的激活，以引发抗肿瘤免疫反应，这也解释了 Th9 细胞控制肿瘤生长的显著能力。这篇综述总结了癌症中 Th9 领域的最新进展，并重点介绍了它们作为细胞治疗新工具的潜在作用。
